Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: A double-blind, randomized, factorial-design, controlled trial

American Journal of Clinical Nutrition

Volumn 67, Issue 5, 1998, Pages 858-866

  Woodside, Jayne V ^a   Yarnell, John W G ^b   McMaster, Dorothy ^b   Young, Ian S ^b   Harmon, Dawn L ^b   McCrum, Evelyn E ^b   Patterson, Chris C ^b   Gey, K Fred ^b   Whitehead, Alexander S ^b   Evans, Alun ^b  

^a Institute of Clinical Sciences B   (United Kingdom)

^b NONE

Author keywords

Antioxidant vitamins; B group vitamins; Cardiovascular disease; Cobalamin; Folate; Homocysteine; Hyperhomocysteinemia; Men; Northern Ireland; Pyridoxal 5' phosphate

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; VITAMIN B GROUP;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FACTORIAL ANALYSIS; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

EID: 19244377848     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/67.5.858     Document Type: Article

References (67)

1. Selhub J, Jacques PR Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
2. Malinow MR. Hyperhomocyst(e)ine: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990;81:2004-6.
3. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerosis Risk in Communities Study. Circulation 1993;87:1107-13.
4. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
5. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
6. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
7. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AC. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
8. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
9. Taylor LM, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vase Surg 1991;13:128-36.
10. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Wilett WC, Stampfer MJ, A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924-30.
11. 6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996;15:136-43.
12. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
13. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974:291:537-43.
14. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalysed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-6.
15. Parthasarathy S. Oxidation of low density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987:917:337-40.
16. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulphur-containing amino acids in Superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-103.
17. Heinecke JW, Lawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 1993;34:2051-61.
18. Blom HJ, Kleinveld HA, Boers GHJ, et al. Lipid peroxidation and susceptibility of low-density-lipoprotein to in-vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995;25:149-54.
19. Halvorsen B, Brude I, Drevon CA, et al. Effect of homocysteine on copper ion-catalysed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. J Lipid Res 1996;37:1591-600.
20. Kottke-Marchant K, Green R, Jacobsen D, Dicorleto P, Sub-cytotoxic homocysteine increases monocyte adhesion to human aortic endothelial cells. Blood 1990;76:511 (abstr).
21. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
22. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocyst(e)ine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764-79.
23. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994;59:940-8.
24. Miller JW, Ribaya-Mercado JD, Russell RM, et al. Effect of vitamin B6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992;55:1154-60.
25. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B-6, B-12 and folate. Am J Epidemiol 1996;143:845-59.
26. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995;346:85-9.
27. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
28. National Research Council. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press, 1989.
29. Brattström L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis 1990;81:51-60.
30. Brattström LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
31. Allen RH, Stabler SP, Savage DG, Lindebaum J. Diagnosis of cobalamin deficiency 1: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Haematol 1990;34:90-8.
32. Malinow MR, Ducimetiere P, Luc G, et al. Plasma homocyst(e)ine concentrations and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996;126:27-34.
33. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular mortality. Lancet 1997;349:397.
34. Davidson S, Passmore R, Brock JF, Trinswell AS. Human nutrition and dietetics. 7th ed. Edinburgh: Churchill, 1979.
35. Basu TK, Schorah CJ. Vitamin C in health and disease. London: Croom Helm, 1982.
36. Jacob RA, Otradovec CL, Russell RM, et al. Vitamin C status and nutrient interactions in a healthy elderly population. Am J Clin Nutr 1988;48:1436-42.
37. Jacob RA, Kelley DS, Pianalto FS, et al. Immunocompetence and oxidant defense during ascorbate depletion of healthy men. Am J Clin Nutr 1991;54(suppl):1302S-9S.
38. EEC Scientific Committee for Food. Reference nutrient intakes for the European community. Brussels: EEC, 1992.
39. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992;3:194-202.
40. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
41. Stampfer MJ, Hennekens CH, Manson JA-E, et al. Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med 1993;328:1444-9.
42. Gey KF, Moser UK, Jordan P, Stähelin HB, Eichholzer M, Lüdin E. Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am J Clin Nutr 1993;57(suppl):787S-97S.
43. Riemersma RA, Wood DA, Macintyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C and E and carotene. Lancet 1991;337:1-5.
44. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
45. Harmon DL, Woodside JV, Yarnell JWG, et al. The common "thermolabile" variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med 1996;89:571-7.
46. Vuillemier JP, Keck E. Fluorometric assay of vitamin C in biological materials using a centrifugal analyser with fluorescence attachment. J Micronutr Anal 1989;5:25-34.
47. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high-performance liquid Chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991;565:441-6.
48. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
49. 6 in human serum. J Liquid Chromatogr 1992;15:897-914.
50. Catignani GL, Bieri JG, Driskell WJ. Simultaneous determination of retinol and alpha-tocopherol in serum or plasma by liquid chromatography. Clin Chem 1983;29:708-12.
51. Thurnham DI, Smith E, Flora PS. Concurrent liquid-chromatographic assay of retinol, α-tocopherol, β-carotene, α-carotene, lycopene, and β-cryptoxanthin in plasma, with tocopherol acetate as internal standard. Clin Chem 1988;34:377-81.
52. Armitage P, Berry G. Statistical methods in medical research. Oxford, United Kingdom: Blackwell Scientific Productions, 1994.
53. Jordan P, Brubacher D, Moser U, Stahelin HB, Gey KF. Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression. Clin Chem 1995;41:924-7.
54. Gey KF. Ten-year retrospective on the antioxidant hypothesis of arteriosclerosis: threshold plasma levels of antioxidant micronutrients related to minimum cardiovascular risk. Nutr Biochem 1995;6:206-36.
55. Bamji MS. Laboratory tests for the assessment of vitamin nutritional status. In: Briggs MH, ed. Vitamins in human biology and medicine. Boca Raton, FL: CRC Press, 1981:1-27.
56. Suter PM, Russell RM. Vitamin requirements of the elderly. Am J Clin Nutr 1987;45:501-12.
57. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994;60:2-11.
58. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
59. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA 1995;274:1526-33.
60. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, ed. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker Inc, 1992:183-236.
61. van den Berg H, Finglas PM, Bates C. FLAIR intercomparisons on serum and red cell folate. Int J Vitam Nutr Res 1994;64:288-93.
62. Robinson K, Mayer E, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-30.
63. Ubbink JB, Vermaak WJH, Van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927-33.
64. Beck WS. Diagnosis of megaloblastic anemia. Annu Rev Med 1991;42:311-22.
65. Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
66. Ubbink JB, van der Merwe A, Delport R, et al. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996;98:177-84.
67. 6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vase Surg 1994;20:933-40.